-- Days : -- HRS : -- MIN : -- SEC

Register Now →

News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|December 16, 2025

Dose Reducing and Sequencing Therapies in Desmoid Tumors

Author(s)Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA , Mrinal Gounder, MD, Gina D'Amato, MD

Experts discuss dose reduction strategies and emerging therapies for desmoid tumors, emphasizing patient monitoring and quality of life improvements.

Episodes in this series

EP. 1 Key Background Information on Desmoid Tumors

EP. 1 Key Background Information on Desmoid Tumors

EP. 2 Exploring the Heterogeneous Nature of Desmoid Tumors

EP. 2 Exploring the Heterogeneous Nature of Desmoid Tumors

EP. 3 The Role of Molecular Biomarkers in Diagnosing Desmoid Tumors

EP. 3 The Role of Molecular Biomarkers in Diagnosing Desmoid Tumors

EP. 4 The Burden and Unmet Needs Associated with Desmoid Tumors

EP. 4 The Burden and Unmet Needs Associated with Desmoid Tumors

EP. 5 When to Observe Desmoid Tumors

EP. 5 When to Observe Desmoid Tumors

EP. 6 Surgery, Cryotherapy, and Radiotherapy for Desmoid Tumors

EP. 6 Surgery, Cryotherapy, and Radiotherapy for Desmoid Tumors

EP. 7 Novel Pharmacotherapies and NCCN Guideline Recommendations

EP. 7 Novel Pharmacotherapies and NCCN Guideline Recommendations

EP. 8 Examining a Novel FDA-approved Therapy in Desmoid Tumors

EP. 8 Examining a Novel FDA-approved Therapy in Desmoid Tumors

EP. 9 Dose Reducing and Sequencing Therapies in Desmoid Tumors

EP. 9 Dose Reducing and Sequencing Therapies in Desmoid Tumors

EP. 10 Insurance Coverage and Patient Education

EP. 10 Insurance Coverage and Patient Education

EP. 11 Additional Clinical Considerations for Desmoid Tumors

EP. 11 Additional Clinical Considerations for Desmoid Tumors

EP. 12 Optimizing Patient Care and the Potential of Artificial Intelligence

EP. 12 Optimizing Patient Care and the Potential of Artificial Intelligence

EP. 13 Unmet Needs and the Future of Desmoid Tumor Management

EP. 13 Unmet Needs and the Future of Desmoid Tumor Management

Panelists discuss the questions below in this video.

When is it appropriate to dose reduce with nirogacestat and how can this ensure the desired clinical outcomes are met?
How are you sequencing therapies in your institution?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Vitamin D3 | Image Credit: Adisak - stock.adobe.com

High-Dose Vitamin D3 Fails to Improve PFS in Phase 3 Metastatic CRC Trial

ByBrooke McCormick

August 6th 2026

Katherine Wilemon, CEO of the Family Heart Foundation

Almost No Public Awareness of Lp(a), Elevated CVD Risk in the US: Katherine Wilemon

ByPearl Steinzor,Katherine Wilemon

August 6th 2026

Eosinophilic esophagitis | Image Credit: syahrir - stock.adobe.com

Patients With MASLD Had More Than 2 Times Higher Odds of Eosinophilic Esophagitis Across Age Groups

ByBrooke McCormick

August 6th 2026

Experts featured in this series.

Translating PFS Data for Patients: How Community Oncologists Communicate Trial Outcomes in RRFL

ByRyan Haumschild, PharmD, MS, MBA, CPEL,Christina Poh, MD,Tara Graff DO, MS

August 6th 2026

Avoiding TNF Cycling: When to Switch Drug Classes in Rheumatoid Arthritis

ByJulia Buchfuhrer, DO

August 6th 2026

Trending on AJMC

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

OneOncology Partners With OpenEvidence to Give Physicians Access Within Clinical Workflows

High-Dose Vitamin D3 Fails to Improve PFS in Phase 3 Metastatic CRC Trial

Patients With MASLD Had More Than 2 Times Higher Odds of Eosinophilic Esophagitis Across Age Groups

AHA Proposes Staging System for Pediatric Cardiogenic Shock